HC Wainwright Issues Positive Estimate for BCRX Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Analysts at HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for BioCryst Pharmaceuticals in a report issued on Tuesday, June 30th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings of $0.05 per share for the quarter, up from their previous forecast of $0.02. HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2026 earnings at ($2.74) EPS, FY2027 earnings at $0.55 EPS, FY2028 earnings at $0.50 EPS, FY2029 earnings at $1.12 EPS and FY2030 earnings at $2.49 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The firm had revenue of $156.41 million for the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The company’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.20 EPS.

A number of other equities analysts also recently commented on BCRX. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Needham & Company LLC reduced their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Wedbush decreased their price target on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Citizens Jmp boosted their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, May 7th. Finally, Cantor Fitzgerald raised their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Tuesday. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $21.67.

BioCryst Pharmaceuticals Trading Down 3.5%

BCRX stock opened at $9.65 on Thursday. The stock’s 50 day simple moving average is $8.92 and its 200 day simple moving average is $8.30. BioCryst Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $10.94. The firm has a market cap of $2.45 billion, a P/E ratio of -5.42 and a beta of 0.55.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently bought and sold shares of BCRX. Royal Bank of Canada raised its position in BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 1,458 shares during the period. Cetera Investment Advisers boosted its stake in shares of BioCryst Pharmaceuticals by 13.8% during the 4th quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 1,494 shares during the period. Captrust Financial Advisors grew its holdings in shares of BioCryst Pharmaceuticals by 7.4% during the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock valued at $198,000 after acquiring an additional 1,527 shares in the last quarter. Counterweight Ventures LLC boosted its position in BioCryst Pharmaceuticals by 2.1% during the fourth quarter. Counterweight Ventures LLC now owns 95,384 shares of the biotechnology company’s stock valued at $744,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.